D&D Pharmatech Confident As It Takes On Parkinson’s, Alzheimer’s
Among Top Global Biotech Fundraisers Last Year
Executive Summary
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.
You may also be interested in...
GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
Asia Deal Watch: LianBio Partners With Pfizer In Greater China, Gets Financial Backing
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
Rising COVID-19 Disruption Of Korea's Global R&D
As the prolonged COVID-19 pandemic continues to take a toll globally, South Korean pharma firms’ overseas drug development activities are increasingly being disrupted by the impact.
Need a specific report? 1000+ reports available
Buy Reports